Abstract
Traditional production of therapeutic glycoproteins relies on mammalian cell culture technology. Glycoproteins produced by mammalian cells invariably display N-glycan heterogeneity resulting in a mixture of glycoforms the composition of which varies from production batch to production batch. However, extent and type of N-glycosylation has a profound impact on the therapeutic properties of many commercially relevant therapeutic proteins making control of N-glycosylation an emerging field of high importance. We have employed a combinatorial library approach to generate glycoengineered Pichia pastoris strains capable of displaying defined human-like N-linked glycans at high uniformity. The availability of these strains allows us to elucidate the relationship between specific N-linked glycans and the function of glycoproteins. The aim of this study was to utilize this novel technology platform and produce two human-like N-linked glycoforms of recombinant human lactoferrin (rhLF), sialylated and non-sialylated, and to evaluate the effects of terminal N-glycan structures on in vitro secondary humoral immune responses. Lactoferrin is considered an important first line defense protein involved in protection against various microbial infections. Here, it is established that glycoengineered P. pastoris strains are bioprocess compatible. Analytical protein and glycan data are presented to demonstrate the capability of glycoengineered P. pastoris to produce fully humanized, active and immunologically compatible rhLF. In addition, the biological activity of the rhLF glycoforms produced was tested in vitro revealing the importance of N-acetylneuraminic (sialic) acid as a terminal sugar in propagation of proper immune responses.
Similar content being viewed by others
Abbreviations
- Man:
-
mannose
- Gal:
-
galactose
- GlcNAc:
-
N-acetylglucosamine
- Sia:
-
sialic acid
- hLF:
-
human lactoferrin
- rhLF:
-
recombinant human lactoferrin
- anti-hLF:
-
anti-human LF antibody
- anti-HCP:
-
anti-host cell protein antibody
- CV:
-
column volume
- AFC:
-
antibody forming colonies
- MALDI-TOF:
-
matrix-assisted laser desorption/ionization time of flight
- MS/MS:
-
tandem mass spectrometry
References
Artym, J., Zimecki, M., Kruzel, M.L.: Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice. Anticancer Res. 24, 3831–3836 (2004)
Baveye, S., Elass, E., Mazurier, J., Spik, G., Legrand, D.: Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 37, 281–286 (1999)
Bayens, R.D., Bezwoda, W.R.: Lactoferrin and the inflammatory response. Adv. Exp. Med. Biol. 357, 133–141 (1994)
Berney, C., Herren, S., Power, C.A., Gordon, S., Martinez-Pomares, L., Kosco-Vilbois, M.H.: A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein. J. Exp. Med. 190, 851–860 (1999)
Bobrowicz, P., Davidson, R.C., Li, H., Potgieter, T.I., Nett, J.H., Hamilton, S.R., Stadheim, T.A., Miele, R.G., Bobrowicz, B., Mitchell, T., Rausch, S., Renfer, E., Wildt, S.: Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology (Oxf.) 14, 757–766 (2004)
Bradford, M.M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976)
Cerwenka, A., Swain, S.L.: TGF-beta1: immunosuppressant and viability factor for T lymphocytes. Microbes Infect. 1, 1291–1296 (1999)
Choi, B.K., Bobrowicz, P., Davidson, R.C., Hamilton, S.R., Kung, D.H., Li, H., Miele, R.G., Nett, J.H., Wildt, S., Gerngross, T.U.: Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl. Acad. Sci. U. S. A. 100, 5022–5027 (2003)
Cornish, J., Callon, K.E., Naot, D., Palmano, K.P., Banovic, T., Bava, U., Watson, M., Lin, J.M., Tong, P.C., Chen, Q., Chan, V.A., Reid, H.E., Fazzalari, N., Baker, H.M., Baker, E.N., Haggarty, N.W., Grey, A.B., Reid, I.R.: Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 145, 4366–4374 (2004)
Crocker, P.R., Kelm, S., Dubois, C., Martin, B., McWilliam, A.S., Shotton, D.M., Paulson, J.C., Gordon, S.: Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. EMBO J. 10, 1661–1669 (1991)
Curran, C.S., Demick, K.P., Mansfield, J.M.: Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways. Cell. Immunol. 242, 23–30 (2006)
Davidson, R.C., Nett, J.H., Renfer, E., Li, H., Stadheim, T.A., Miller, B.J., Miele, R.G., Hamilton, S.R., Choi, B.K., Mitchell, T.I., Wildt, S.: Functional analysis of the ALG3 gene encoding the Dol-P-Man: Man5GlcNAc2-PP-Dol mannosyltransferase enzyme of P. pastoris. Glycobiology (Oxf.) 14, 399–407 (2004)
Derisbourg, P., Wieruszeski, J.M., Montreuil, J., Spik, G.: Primary structure of glycans isolated from human leucocyte lactotransferrin. Absence of fucose residues questions the proposed mechanism of hyposideraemia. Biochem. J. 269, 821–825 (1990)
Frei, K., Steger, C., Samorapoompichit, P., Lucas, T., Forster, O.: Expression and function of sialoadhesin in rat alveolar macrophages. Immunol. Lett. 71, 167–170 (2000)
Gerngross, T.U.: Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 22, 1409–1414 (2004)
Hamilton, S.R., Bobrowicz, P., Bobrowicz, B., Davidson, R.C., Li, H., Mitchell, T., Nett, J.H., Rausch, S., Stadheim, T.A., Wischnewski, H., Wildt, S., Gerngross, T.U.: Production of complex human glycoproteins in yeast. Science 301, 1244–1246 (2003)
Hamilton, S.R., Davidson, R.C., Sethuraman, N., Nett, J.H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T.A., Li, H., Choi, B.K., Hopkins, D., Wischnewski, H., Roser, J., Mitchell, T., Strawbridge, R.R., Hoopes, J., Wildt, S., Gerngross, T.U.: Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313, 1441–1443 (2006)
Hwang, S.A., Kruzel, M.L., Actor, J.K.: Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int. Immunopharmacol. 5, 591–599 (2005)
Hwang, S.A., Wilk, K.M., Bangale, Y.A., Kruzel, M.L., Actor, J.K.: Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med. Microbiol. Immunol. 196, 171–180 (2007)
Kelm, S., Pelz, A., Schauer, R., Filbin, M.T., Tang, S., de Bellard, M.E., Schnaar, R.L., Mahoney, J.A., Hartnell, A., Bradfield, P., et al.: Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr. Biol. 4, 965–972 (1994)
Kruzel, M.L., Harari, Y., Mailman, D., Actor, J.K., Zimecki, M.: Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol. 130, 25–31 (2002)
Kruzel, M.L., Zimecki, M.: Lactoferrin and immunologic dissonance: clinical implications. Arch. Immunol. Ther. Exp. 50, 399–410 (2002)
Legrand, D., Salmon, V., Coddeville, B., Benaissa, M., Plancke, Y., Spik, G.: Structural determination of two N-linked glycans isolated from recombinant human lactoferrin expressed in BHK cells. FEBS Lett. 365, 57–60 (1995)
Li, H., Sethuraman, N., Stadheim, T.A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.K., Cook, W.J., Cukan, M., Houston-Cummings, N.R., Davidson, R., Gong, B., Hamilton, S.R., Hoopes, J.P., Jiang, Y., Kim, N., Mansfield, R., Nett, J.H., Rios, S., Strawbridge, R., Wildt, S., Gerngross, T.U.: Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24, 210–215 (2006)
Loginov, A.V., Uteshev, B.S., Livshits, M.A.: [Mathematical modelling of the action of methotrexate on the kinetics of B-lymphocyte proliferation during the primary response]. Farmakol. Toksikol. 50, 58–70 (1987)
Lonnerdal, B., Iyer, S.: Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr. 15, 93–110 (1995)
Mishell, R.I., Dutton, R.W.: Immunization of dissociated spleen cell cultures from normal mice. J. Exp. Med. 126, 423–442 (1967)
Nakamura, K., Yamaji, T., Crocker, P.R., Suzuki, A., Hashimoto, Y.: Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin: implication for the adhesive properties of macrophages in vivo. Glycobiology (Oxf.) 12, 209–216 (2002)
Naot, D., Grey, A., Reid, I.R., Cornish, J.: Lactoferrin—a novel bone growth factor. Clin. Med. Res. 3, 93–101 (2005)
Samyn-Petit, B., Wajda Dubos, J.P., Chirat, F., Coddeville, B., Demaizieres, G., Farrer, S., Slomianny, M.C., Theisen, M., Delannoy, P.: Comparative analysis of the site-specific N-glycosylation of human lactoferrin produced in maize and tobacco plants. Eur. J. Biochem. 270, 3235–3242 (2003)
Sanchez, L., Calvo, M., Brock, J.H.: Biological role of lactoferrin. Arch. Dis. Child 67, 657–661 (1992)
Spik, G., Coddeville, B., Montreuil, J.: Comparative study of the primary structures of sero-, lacto- and ovotransferrin glycans from different species. Biochimie. 70, 1459–1469 (1988)
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., Akira, S.: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161, 4652–4660 (1998)
van’t Land, B., van Beek, N.M., van den Berg, J.J., M’Rabet, L.: Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation. Dig. Dis. Sci. 49, 425–433 (2004)
van Berkel, P.H., van Veen, H.A., Geerts, M.E., de Boer, H.A., Nuijens, J.H.: Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. Biochem. J. 319(Pt 1), 117–122 (1996)
Wang, S.H., Yang, T.S., Lin, S.M., Tsai, M.S., Wu, S.C., Mao, S.J.: Expression, characterization, and purification of recombinant porcine lactoferrin in Pichia pastoris. Protein Expr. Purif. 25, 41–49 (2002)
Wei, Z., Nishimura, T., Yoshida, S.: Characterization of glycans in a lactoferrin isoform, lactoferrin-a. J. Dairy Sci. 84, 2584–2590 (2001)
Weis, W.I., Taylor, M.E., Drickamer, K.: The C-type lectin superfamily in the immune system. Immunol. Rev. 163, 19–34 (1998)
Yoo, J.K., Cho, J.H., Lee, S.W., Sung, Y.C.: IL-12 provides proliferation and survival signals to murine CD4+ T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J. Immunol. 169, 3637–3643 (2002)
Zielinski, C.C., Stuller, I., Dorner, F., Potzi, P., Muller, C., Eibl, M.M.: Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer 58, 1648–1652 (1986)
Zimecki, M., Artym, J., Chodaczek, G., Kocieba, M., Kruzel, M.: Effects of lactoferrin on the immune response modified by the immobilization stress. Pharmacol. Rep. 57, 811–817 (2005)
Zimecki, M., Kocieba, M., Kruzel, M.: Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology 205, 120–131 (2002)
Zimecki, M., Kruzel, M.L.: Milk-derived proteins and peptides of potential therapeutic and nutritive value. J. Exp. Ther. Oncol. 6, 89–106 (2007)
Zimecki, M., Mazurier, J., Spik, G., Kapp, J.A.: Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 86, 122–127 (1995)
Zimecki, M., Mazurier, J., Spik, G., Kapp, J.A.: Lactoferrin (LF) lowers IgM and interleukin 2 receptor expression on WEHI 231 cells and decreases anti-IgM antibody-induced cell death. In: VIII Meeting of the Polish Immunological Society, Wroclaw, Poland, Pol. J. Immunol. 324 (1995)
Zimecki, M., Miedzybrodzki, R., Mazurier, J., Spik, G.: Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells. Arch. Immunol. Ther. Exp. 47, 257–264 (1999)
Acknowledgments
This research was supported by the National Institutes of Health: R42AI051050-02 and R41GM079810-01. We thank Teresa Mitchell for the technical assistant and Bing Gong for the critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, BK., Actor, J.K., Rios, S. et al. Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj J 25, 581–593 (2008). https://doi.org/10.1007/s10719-008-9123-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10719-008-9123-y